You can narrow down the results using the filters
-
A Phase 1c, Single Centre Study Investigating the Safety and Tolerability of a Lysyl Oxidase Inhibitor (PXS-6302) vs Placebo in the Amelioration of Established Scars.
Expand descriptionScar formation following a burn or surgery is a considerable health issue worldwide. Current options to manage established scars are mostly invasive and include cryotherapy, scar revision surgery or laser therapy. Lysyl oxidase (LOX) a novel compound is a copper-dependent amine oxidase that plays a critical role in the biogenesis of connective tissue matrices by crosslinking the extracellular matrix proteins, collagen and elastin. Recent studies have revealed a crucial role for LOX in skin fibrosis including the potential to reduce scar formation. This study aims to investigate the safety and tolerability of PXS-6302 for the amelioration of scars in a formulated topical cream.
-
An evaluation of an information linker service for families with a child diagnosed with genetic epilepsy.
Expand descriptionWe will conduct a pilot of ‘GenE Compass’, an information linkage service for families of a child with a suspected or confirmed diagnosis of a developmental and epileptic encephalopathy (DEE). GenE Compass answers caregivers’ questions about their child’s DEE: for example expected co-morbidities, natural history information, support resources, what current research is being conducted on that condition. Primary outcomes 1. Is GenE Compass acceptable to caregivers and healthcare professionals? 2. Is GenE Compass feasible to deliver? Secondary outcomes 3. What is the potential impact of GenE Compass, if any, on caregivers, healthcare professionals and the healthcare system? We will include caregivers who have a child (<18 years of age) with a suspected or confirmed diagnosis of DEE (e.g. SCN2A-encephalopathy , WWOX- encephalopathy), who are new or existing patients of the Sydney Children’s Hospitals Network and speak English. We will also include healthcare professionals who have been nominated by the caregiver to receive the reports. Following consent, caregivers will complete Questionnaire 1. They will then be provided access to GenE Compass. Our linker service will triage questions (Level A or B). Level A questions are defined as out of scope of GenE Compass, can be best responded to by a known alternative service/organisation, or simple response required OR consists of a clinical question which will need to be addressed by one of the child’s clinicians as greater context is required. For Level A questions, the linker will respond to the caregiver via email within a few business days to inform them it is either outside the scope of GenE Compass or the more appropriate organisation to support them (e.g. Reframing Disability for questions related to NDIS access). Level B queries are defined as related to information about a DEE or comorbidities, but not direct patient care (i.e. within scope of GenE Compass). For Level B questions, the linker will conduct a rapid literature search and consult with our expert multidisciplinary team. We will then send caregivers and their nominated healthcare professionals (Neurologist, Paediatrician and/or GP) back a report within 5-10 business days. After 3-months of access to GenE Compass, we will invite caregivers to complete Questionnaire 2 and an optional telephone interview. We will also invite the nominated healthcare professionals to complete a questionnaire at study close.
-
Queensland COVID-19 Vaccination (QoVAX) Safety and Efficacy Trial Pilot Study in adults aged 18 years and over.
Expand descriptionThe QoVax SET research pilot study is designed to investigate intrinsic and extrinsic host and viral determinants of vaccine safety, immunity and efficacy in Queensland. Specifically, the QoVax SET Program seeks to determine whether the vaccines administered by Queensland Health facilities are safe and effective in the Queensland community to; • Induce SARS-CoV2 immunity, • Limit the severity of virus-induced disease, and • Sustain immunity and protection from SARS-CoV2 disease in QLD.
-
A Single Microdose Study to Evaluate the Pharmacokinetics of INS018_055 in Healthy Participants
Expand descriptionThis is First in human, open label, single centre, exploratory study to determine safety and PK characteristics of INS018_055 after a single IV microdose administration in healthy participants. This study will enrol 8 eligible adults. The study will consist of 3 periods: Screening-(Day -28 to Day-1)- After completion of ICF and eligibility check participants will be enrolled in the study. Treatment period (Day-1 to Day -2)- On Day 1, baseline and safety assessments will be performed and participants will be administered a single dose of IP via IV injection and monitored for safety. Blood for PK analysis will be collected pre and post dosing. Follow up (Day 8[± 1day]- Participants will return to CRU on Day 8 to undergo safety assessments.
-
A Single and Multiple Dose Escalation Study in Healthy Participants to Evaluate Safety, Tolerability and Pharmacokinetics of ABI-2280 Vaginal Gel and Tablets as Applied to the Cervix
Expand descriptionAntiva is developing ABI-2280, a potent human DNA polymerase inhibitor, for topical treatment of several precancerous conditions related to human papillomavirus (HPV) infection, including high grade squamous intraepithelial lesions (HSIL) of the cervix. The purpose of this study is to assess the safety, tolerability and PK of ABI-2280 Vaginal Gel and Tablet, applied to the cervix of healthy female participants. The study will be conducted in two parts: Part A (Single Ascending Dose) and Part B (Multiple Ascending Dose). Part A There will be 4 Cohorts in this part, A1 -A4, each consisting of 8 participants. 6 participants will receive a single dose of ABI-2280 and 2 will receive a single dose of placebo. No participant will be enrolled in more than one cohort. Participants will be screened up to 49 days prior to dose administration. Participants may be admitted to research unit on Day -1 or morning of Day 1 and remain admitted until Day 2. On Day 1 participants will receive a single dose of ABI-2280 Vaginal Gel or Tablet or placebo. They will return to the clinic on Day 4 for safety follow up visit and Day 8 for end of study visit. Part B Up to approximately 16 participants will be enrolled into two cohorts- B1 and B2. Each cohort will consist of 8 participants (6 to receive ABI-2280 Vaginal Gel or Tablet and 2 to receive placebo). Participants will be screened up to 49 days prior to Day 1 dose administration. For cohorts B1 and B2, participants may be admitted to the research unit on Days -1 and 4 and discharged on Days 2 & 6 or if feasible, may be admitted through Day -1 to Day 5 and discharged on Day 6. On Days 1 & 5, they will receive the first and last doses of ABI-2280 Vaginal Gel or Tablet or placebo. Participants will have safety assessments and ABI-2280 or placebo administration on Days 3, safety follow-up visit on Day 9, and the End of Study (EOS) visit on Day 15.
-
Clozapine Obesity and Semaglutide Treatment (COaST). A randomised controlled multi-centre trial of semaglutide versus placebo for people with schizophrenia on clozapine with obesity
Expand descriptionThe study will be a randomised, placebo-controlled single-blind parallel-group trial; over a 36 week period. The primary objective in this study is to determine percentage change in body weight with 36 week treatment with subcutaneous semaglutide versus placebo, adjusted for baseline weight period for patients with schizophrenia or schizoaffective disorder. Specifically, it is hypothesised those participants allocated to the active arm semaglutide treatment will have a greater reduction of percentage body weight at week 36 compared to individuals taking placebo.
-
Feasibility and effects of a pragmatic home-based resistance ‘exercise snacking’ program on physical function in older adults living independently.
Expand descriptionThis 4-week pilot study aimed to determine the feasibility and acceptability of performing a pragmatic resistance ‘exercise snacking’ program performed once, twice, or thrice daily in community-dwelling older adults when delivered and monitored remotely. Secondary aims were to: 1) explore the dose-response effects of ‘exercise snacking’ on physical function, 2) determine the feasibility of conducting physical function assessments remotely within the homes of participants using videoconferencing, and 3) explore the participants experience and perceptions of the ‘exercise snacking’ approach. It was hypothesised that the exercise program would be feasible (mean of 80% of prescribed sessions completed) for all daily exercise frequencies and it would also be feasible to perform the physical function assessments remotely using videoconferencing.
-
Safety and Efficacy of NOX66 in combination with Nivolumab for patients with solid tumours – a pilot study (IONIC-1).
Expand descriptionThis trial aims to determine whether NOX66 (idronoxil) can be safely given in combination with nivolumab (an immune checkpoint inhibitor) and to determine the highest dose of NOX66 that can be administered safely. Who is it for? You may be eligible for this study if you are aged 18 or older, you have a confirmed diagnosis of solid advanced, metastatic tumour that is potentially amenable to treatment with nivolumab. You may already be receiving a checkpoint inhibitor (nivolumab or other) and have minor disease progression, or you may have minor disease progression on chemo- or targeted therapy and have never received a checkpoint inhibitor. Study details Participants who choose to enrol in this study will undergo 14-day treatment cycles with nivolumab, which will be administered via a needle into their vein on the first treatment day. Participants will also receive NOX66 as a suppository on days 1-7 of each treatment cycle. Combination treatment may continue for up to 2 years. Continuation of the combined treatments will depend upon whether the treatments have an effect on tumour growth and whether participants experience any significant side effects while on treatment. During the treatment cycles all participants will be monitored for side effects and will also undergo imaging (CT or MRI) at 2, 4, 6, 12 and 18 months after the start of Cycle 1, and at the End of Study (Month 24) or Early Termination. Bone scans will also be performed in patients where the cancer has spread to the bones. Bone scan will be done at screening if no recent scan (within 6 weeks), and at 6, 12, 18 and 24 months after the start of Cycle 1. It is hoped this research will demonstrate that NOX66 in combination with nivolumab is safe and that the optimal dose of NOX66 for the treatment of solid tumours can be determined. If NOX66 and nivolumab are shown to be safe and effective, these treatments may be used to improve outcomes for future cancer patients.
-
High volume versus low volume supra scapular nerve block in patients with rotator cuff tears
Expand descriptionThis study aims to determine if high volume HCLA SSNB injection leads to decreased pain and improved functional outcomes, when compared with low volume injection in patients with rotator cuff tears. This will be a landmark study for SSNB HCLA injection volumes in the literature. This research will help create a standardised process for the administration of HCLA SSNB injections. At present, there is no protocol or guidelines in place that guide SSNB volumes. Evidence based processes could be created with this research and will have the effect of reliable and reproducible treatment which increase the efficacy and safety of treatment for patients.
-
Ivermectin to prevent Coronavirus
Expand description